Evotec's Horizon restructuring reshapes CRO outsourcing calculus

For pharma manufacturers evaluating external development alliances, Evotec's Q1 2026 results signal that the CRO's internal restructuring is now in active execution, and the shape of its service model is changing in ways that affect partnership terms, platform access, and delivery timelines.

Evotec enters Horizon implementation phase amid Q1 revenue softness

Evotec SE reported group revenues of €156.6 million for Q1 2026 (€166.9 million at constant exchange rates), down against a prior-year comparison that included a significant one-off contribution. Adjusted Group EBITDA came in at -€21.9 million (-€18.9 million at CER), with foreign exchange headwinds and one-off effects cited as primary drivers. Full-year 2026 guidance was confirmed, with management indicating the financial profile is expected to improve as the year progresses.

The Horizon transformation, Evotec's structured operating model overhaul, moved from planning into implementation during the quarter. Actions underway include streamlining operations, reducing the cost base, and improving site utilization. Leadership additions in commercial and operations functions were made to support execution, including the appointment of Dr. Ingrid Müller as Chief Operating Officer and the transition of Claire Hinshelwood into the Chief Financial Officer role.

What QA and alliance leads should track in the INDiGO platform build-out

For QA directors and alliance managers at sponsor companies, the more operationally relevant signal is Evotec's continued investment in its INDiGO platform, an integrated end-to-end capability designed to advance small molecules from candidate nomination through IND submission. The platform's AI/ML-enabled architecture underpins two partnership milestones reported this quarter.

In the Almirall collaboration targeting inflammatory skin diseases, Evotec nominated its first preclinical development candidate (PDC) in May 2026, moving from lead identification to PDC nomination in approximately two years, a compressed timeline relative to conventional industry benchmarks. Separately, the Gates Foundation awarded two new grants in April 2026 to advance tuberculosis drug discovery, including nonclinical evaluation of next-generation drug combinations and long-acting injectable approaches. Both programs leverage Evotec's AI-enabled translational platforms for candidate selection and development risk reduction.

Read against the Horizon restructuring, these milestones carry a dual signal: the platform is producing results under operational pressure, but sponsors entering new agreements should assess how site consolidation and utilization changes under Horizon may affect dedicated resource allocation and GMP-readiness timelines for their programs.

Where the Horizon timeline intersects with outsourcing decisions in H2 2026

Evotec's management has indicated that Horizon benefits are expected to build through 2026, with the financial profile improving progressively. For regulatory affairs leads and CMC teams at companies with active or prospective Evotec engagements, the practical checkpoint is how operational changes at the CRO level translate into IND-enabling study timelines and technology transfer readiness under 21 CFR Part 211 and ICH Q10 quality system expectations.

Evotec is scheduled to provide further updates on Horizon progress and D&PD partnership activity as full-year 2026 results are reported, making the H2 2026 earnings cycle the next substantive checkpoint for sponsors monitoring the restructuring's effect on delivery commitments.